ReviewAntibiotics (Basel, Switzerland)2013
Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance.
Review in Antibiotics (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 197 citations in OpenAlex.
- Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- First Randomized Controlled Trial Comparing D-Mannose to Fosfomycin in Acute Uncomplicated Lower Urinary Tract Infections.Antibiotics (Basel, Switzerland) · 2026Article
- Quantifying outer membrane permeability to β-lactam antibiotics using outer membrane vesicles that protect antibiotic-susceptible bacteria.Nature communications · 2026Article
- Fosfomycin Resistance Dynamics in Major Uropathogens: A 2013-2025 Integrated Disease Surveillance of Multidrug-Resistant, Extended-Spectrum Beta-Lactamase-Producing, Non-Extended-Spectrum Beta-Lactamase, and Enterococcal Urinary Isolates.Pathogens (Basel, Switzerland) · 2026Article
- Fosfomycin Resistance in Escherichia coli: Mechanisms, Trends, and Clinical Challenges.Cureus · 2026Review
- Covalent Inhibitors in Antimicrobial Drug Development-Beyond β-Lactams.Molecules (Basel, Switzerland) · 2026Review
- Cranberry juice potentiates sensitivity of uropathogenicApplied and environmental microbiology · 2026Article
- A nutrient bottleneck controls antibiotic efficacy in structured bacterial populations.Nature communications · 2026Article
- Molecular characterisation of fosfomycin resistance genes in Escherichia coli isolates.Folia microbiologica · 2026Article
- Unravelling the Pathotype, Biofilm, Virulome and Resistome Profile of MultiDrug-Resistant Bacteria Isolated From Cattle Faeces Using Whole Genome Sequence Analysis.International journal of microbiology · 2026Article
- Fitness cost and biofilm formation in fosfomycin-resistant clinicalTurkish journal of medical sciences · 2026Article
- The Impacts of Essential Gcp/TsaD Protein on Cell Morphology, Virulence Expression, and Antibiotic Susceptibility inMicroorganisms · 2025Article
- HeterogeneousJournal of medical microbiology · 2025Article
- Fosfomycin resistance determinants in Escherichia coli isolates of human and animal origin from Iran.Molecular biology reports · 2025Article
- Chromosomal genes modulating fosfomycin susceptibility in uropathogenicAntimicrobial agents and chemotherapy · 2025Article
- Overcoming the drug resistance barrier: progress in fosfomycin combination therapy against multidrug-resistant pathogens.Frontiers in microbiology · 2025Review
- The Prevalence and the Underlying Mechanisms of Fosfomycin Resistance ofInternational journal of molecular sciences · 2024Article
- PhoPQ-mediated lipopolysaccharide modification governs intrinsic resistance to tetracycline and glycylcycline antibiotics inmSystems · 2024Article
- The Impact of Fosfomycin on Gram Negative Infections: A Comprehensive Review.Indian journal of microbiology · 2024Review
- Antimicrobial Resistance in Livestock: A Serious Threat to Public Health.Antibiotics (Basel, Switzerland) · 2024Review
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial infections caused by antibiotic-resistant isolates have become a major health problem in recent years, since they are very difficult to treat, leading to an increase in morbidity and mortality. Fosfomycin is a broad-spectrum bactericidal antibiotic that inhibits cell wall biosynthesis in both Gram-negative and Gram-positive bacteria. This antibiotic has a unique mechanism of action and inhibits the initial step in peptidoglycan biosynthesis by blocking the enzyme, MurA. Fosfomycin has been used successfully for the treatment of urinary tract infections for a long time, but the increased emergence of antibiotic resistance has made fosfomycin a suitable candidate for the treatment of infections caused by multidrug-resistant pathogens, especially in combination with other therapeutic partners. The acquisition of fosfomycin resistance could threaten the reintroduction of this antibiotic for the treatment of bacterial infection. Here, we analyse the mechanism of action and molecular mechanisms for the development of fosfomycin resistance, including the modification of the antibiotic target, reduced antibiotic uptake and antibiotic inactivation. In addition, we describe the role of each pathway in clinical isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.